In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.

Inclusion Criteria:

• Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD)
• who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)
• for whom intravitreal injection has already been clinically indicated

Exclusion Criteria:

• Patients younger than 45 years or older than 90 years
• History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months
• Presence of uveitis
• Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract)
• Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema)
• Presence of hereditary retinal dystrophies
• Presence of optic atrophy

Patients aged 45 to 90 years diagnosed with active neovascular (exudative) age-related macular degeneration (nAMD), who are receiving routine ophthalmologic follow-up at a tertiary referral center and have been clinically indicated for intravitreal aflibercept biosimilar (MY-1701P) injection. Participants will be selected based on evidence of disease activity on ophthalmologic examination and optical coherence tomography (OCT) imaging.